Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)

Rani Therapeutics Holdings' Preferred Stock Liabilities history spans 2 years, with the latest figure at $191.0 million for Q2 2021.

  • On a quarterly basis, Preferred Stock Liabilities rose 65.39% to $191.0 million in Q2 2021 year-over-year; TTM through Jun 2021 was $191.0 million, a 65.39% increase, with the full-year FY2020 number at $184.7 million, changed N/A from a year prior.
  • Preferred Stock Liabilities came in at $191.0 million for Q2 2021, roughly flat from $191.0 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $191.0 million in Q1 2021, with the low at $115.5 million in Q2 2020.